StockNews.AI
GOOG
TechCrunch
141 days

Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive

1. Isomorphic Labs raises $600 million to enhance AI drug design. 2. Funding includes investments from Alphabet, Thrive Capital, and GV. 3. Partnerships with Eli Lilly and Novartis may yield $3 billion. 4. Capital will help hire top scientists for further AI development. 5. Nobel Prize recognition enhances Isomorphic's credibility in drug discovery.

3m saved
Insight
Article

FAQ

Why Bullish?

The substantial funding reflects confidence in Isomorphic's potential, similar to past successful spin-offs like Waymo, indicating potential future profitability for Alphabet.

How important is it?

The funding represents a strategic move that can enhance Alphabet’s portfolio in healthcare technology, aligning with broader industry trends.

Why Long Term?

As Isomorphic advances its drug candidates through clinical trials, potential revenue generation could significantly benefit Alphabet’s long-term financial health.

Related Companies

Related News